NEW YORK (GenomeWeb) — Diagnostic tools developer Protagen AG announced this week that it will join the RA-MAP Consortium, a collaboration of 10 universities and 10 companies working together to identify the key predictors of clinical response and remission in rheumatoid arthritis (RA) patients, and to identify those at high risk of developing the disease. Protagen will contribute its proprietary SeroTag diagnostic platform to search for RA biomarkers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.